摘要
目的:探讨复方丹参注射液联合伊马替尼对急性淋巴细胞白血病(ALL)患者P-糖蛋白、P53蛋白水平及心血管功能的影响。方法:随机数字表格法将纳入标准的80例ALL患者分为对照组与观察组,各40例,所有患者均接受VDCP化疗方案治疗,此外对照组加以伊马替尼治疗,观察组则加以复方丹参注射液联合伊马替尼治疗,比较两组近期疗效、不良反应、治疗前后外周血象、免疫功能及心率变异性(HRV)指标,同时治疗前后通过流式细胞仪测定P-糖蛋白及P53蛋白水平。结果:观察组治疗有效率90.00%,较对照组的80.00%差异无统计学意义(P<0.05)。与治疗前比较,治疗后两组WBC水平显著下降,Hb、PLT、RBC水平显著上升(P<0.05)。观察组治疗后WBC、Hb、RBC、CD_3^+、CD_4^+、CD_4^+/CD_8^+、SDNN、SDANN、RMSSD、PNN50水平均明显高于对照组(P<0.05)。观察组治疗后P53阳性表达率较治疗前明显下降,较对照组明显低(P<0.05)。观察组肝功能异常发生率明显低于对照组(P<0.05)。结论:复方丹参注射液联合伊马替尼治疗ALL疗效明确,能有效减少伊马替尼+化疗不良反应,降低P-糖蛋白及P53蛋白阳性表达率,且对患者免疫功能、心率变异性有一定的改善作用。
Objective ：To explore the effects of Compound Danshen Injection combined with imatinib on P- glycoprotein,P53 protein level and cardiovascular function of patients with acute lymphoblastic leukemia （ALL）. Methods：Eighty ALL patients who were in accordance with the accepting criteria were divided by random number table into the observation group and the control group （each 40 cases）. All patients underwent VDCP chemotherapy regimen. The control group added imatinib and the observation group added Compound Danshen Injection combined with imatinib. The short -term effects, adverse reactions and peripheral blood before and after the treatment, immune function and heart rate variability （HRV） indices of the two groups were compared. P -glycoprotein and P53 protein level were measured by flow cytometry before and after the treatment at the same time. Results：There was no significant difference in the effective rate of treatment between the observation group （90.00%） and the control group （ 80.00% ） （ P 〈 0. 05 ）. The levels of WBC in the two groups after the treatment were significantly decreasedand the levels of Hb, PLT and RBC were significantly increased compared with those before treatment （ P 〈 0.05 ）. WBC, Hb, RBC, CD3＋ , CD4 , CD4/CD8 , SDNN, SDANN, RMSSD and PNN50 levels of the observation group after the treatment were significantly higher than those of the control group （ P 〈 0. 05 ）. Positive expression rate of P53 in the observation group after the treatment was significantly decreased than that before the treatment and significantly lower than those of the control group （ P 〈 0. 05 ）. The incidence of abnormal liver function in the observation group was significantly lower than that of the control group （ P 〈 0. 05 ）. Conclusion ： Compound Danshen Injection combined with imatinib has the definite effect on ALL. It can effectively reduce the toxic and side effects of imatinib ＋ chemotherapy, reduce the positive expression rate of P - glyeoprotein and P53 proteinand can improve the immune function and heart rate variability of the patients.
出处
《中华中医药学刊》
CAS
北大核心
2017年第2期425-428,共4页
Chinese Archives of Traditional Chinese Medicine
基金
浙江省自然科学基金项目(2015348572)
